目的 研究Biolight D800(BLT-D800，广东宝莱特医用科技股份有限公司，中国)血滤机的性能。 方法 以Braun Dialog+(贝朗爱敦股份公司，德国)血滤机为对照，采用随机对照法研究国产BLT-D800血滤机性能。选择2022年8月北京积水潭医院贵州医院血液透析中心接受规律血液透析治疗的MHD患者120例，采用随机数字法分为2组(60例/组)，每周3次血液透析(hemodialysis，HD)，每月1次后稀释血液透析滤过(hemodiafiltration，HDF)，对比HDF治疗时血液透析并发症、治疗效果等指标和设备配液情况。 结果 2组患者在HDF治疗过程中，低血压、高血压、肌肉痉挛、胸闷等不良反应发生率差异无统计学意义(χ2=0.178,0.934,0.167,0.164，P=0.677,0.358,0.666,0.873)；BLT-D800组HDF治疗后尿素清除指数(Kt/V)、尿素下降率(URR)、血β2微球蛋白(β2 microglobulin,β2-MG)等指标的改善程度与Braun Dialog+组比较差异无统计学意义(t=-0.426,0.165,0.046，P=0.381,0.692,0.833)；超滤误差对照组更高，2组间差异有统计学意义(t=-14.956，P＜0.001)。 结论 国产BLT-D800血滤机性能稳定，能安全有效开展HDF治疗。
Objective To investigate the performance of domestic Biolight D800 hemofiltration machine (BLT-D800 Guangdong Biolight Meditech CO., China). Method This was a randomized controlled study, using the imported Braun Dialog+ hemofiltration machine (B. Braun Avitum AG, Germany) as the control. A total of 120 patients undergoing maintenance hemodialysis (MHD) at the Blood Purification Center, Guizhou Hospital of Beijing Jishuitan Hospital were recruited for this study. They were divided into 2 groups (n=60/group) by a random number table method. Patients in each group were treated with hemodialysis (HD) 3 times/week and post diluted hemodiafiltration (HDF) once/month. Dialysis complications, treatment effects, dialysate for the machine and other indicators were observed during HDF. Result The ratios of hypotension, hypertension, muscle cramp, and choking sensation in chest were similar between the two groups (χ2=0.178, 0.934, 0.167 and 0.164 respectively; P=0.677, 0.358, 0.666 and 0.873 respectively). After HDF treatment, Kt/V, urea reduction rate (URR) and serum β2 microglobulin (β2-MG) were also similar between the two groups (t= -0.426, 0.165 and 0.046 respectively; P=0.381, 0.692 and 0.833 respectively). Ultrafiltration error was statistically higher in the control group (t=-14.956, P＜0.001). Conclusion The domestic BLT-D800 hemofiltration machine is stable for blood purification performance, and is capable to carry out HDF safely and effectively.
[1] Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study[J]. Nephrol Dial Transplant, 2011, 26(8):2641-2648.
[2] Panichi V, Scatena A, Rosati A, et al. High-volume on-line haemodiafiltration improves erythropoiesis-stimulating agent (ESA) rcsistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study[J]. Nephrol Dial Transplant，2015，30(4): 682-689.
[3] Penne EL, van der Weerd NC, Blankestijn PJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients[J]. Clin J Am Soc Nephrol, 2010,5(1): 80-86.
[4] Morena M, Jaussent A, Chalabi L, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly[J]. Kidney Int, 2017, 91(6):1495-1509.
[5] Mostonaya IM, Blankestijn PJ, Bots ML, et al. Clinicalevidence on hemodiafiltration: a systematic review and a meta-analysis[J]. Semin Dial, 2014, 27(2):119-127.
[6] Lin CL, Huang CC, Yu CC, et al. Reduction of advancedglycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients[J]. Am J Kidney Dis, 2003,42(3):524-531.
[7] Paterier L, Dupuy AM, Granger Vallee A, et al. FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis[J]. Int J Artif Organs, 2006, 29(10):949-955.
[8] Zhang W, Mei C, Chen N, et al. Outcomes and practice patterns with hemodiafiltration in Shanghai: a longitudinal cohort study [J]. BMC Nephrol，2019，20(1): 34.
[9] 汪玫，戴兵，张翼祥，等. 维持性血液透析患者心血管并发症及生存分析研究[J]. 中华肾脏病杂志, 2014, 30(9):665-670.
[10] 于巍，古庆恩，黄世安.脉搏血氧饱和度监测技术的研究进展[J]. 中国医学装备，2008，5（4）：56-58.
